摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氯己酰氯 | 43056-19-5

中文名称
2-氯己酰氯
中文别名
——
英文名称
2-chlorohexanoyl chloride
英文别名
——
2-氯己酰氯化学式
CAS
43056-19-5
化学式
C6H10Cl2O
mdl
——
分子量
169.051
InChiKey
WYVJWHBYNAQOHK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    53-59 °C(Press: 11 Torr)
  • 密度:
    1.143±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    9
  • 可旋转键数:
    4
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    1

SDS

SDS:52e3735401a69e730d7c85b0cf3005ee
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-氯己酰氯 生成 butyl-chloro-ketene
    参考文献:
    名称:
    BELLUS D., HELV. CHIM. ACTA , 1975, 58, NO 8, 2509-2511
    摘要:
    DOI:
  • 作为产物:
    描述:
    参考文献:
    名称:
    Efficient .alpha.-halogenation of acyl chlorides by N-bromosuccinimide, N-chlorosuccinimide, and molecular iodine
    摘要:
    DOI:
    10.1021/jo00911a026
点击查看最新优质反应信息

文献信息

  • 2-(4-噻唑啉酮-2-亚氨基)噻唑-5-羧酸酯及 其制备方法与应用
    申请人:湖南大学
    公开号:CN106632134B
    公开(公告)日:2020-01-03
    本发明涉及化学结构式Ⅰ和Ⅱ所示的2‑(4‑噻唑啉酮‑2‑亚氨基)噻唑‑5‑羧酸酯:其中,R选自:C1~C2烷基、C3~C4直链烷基或C3~C4支链烷基;R1选自:C1~C2烷基、C3~C4直链烷基或C3~C4支链烷基、三氟甲基;Y1选自:氢、C1~C2烷基、C3~C4直链烷基或C3~C4支链烷基、羧基、C1~C2烷氧羰基、羟基、C1~C2烷氧基;Y2、Y4选自:氢、C1~C2烷基、C3~C4直链烷基或C3~C4支链烷基、羟基、C1~C2烷氧基、氟、氯、溴、碘、氨基或硝基;Y3选自:氢、C1~C2烷基、C3~C4直链烷基或C3~C4支链烷基、羧基、C1~C2烷氧羰基、羟基、C1~C2烷氧基、氨基、乙酰氨基或硝基;R2选自:氢、C1~C2烷基、C3~C4直链或C3~C4支链烷基、苯基或C1~C2烷基取代的苯基。2‑(4‑噻唑啉酮‑2‑亚氨基)噻唑‑5‑羧酸酯在制备流感病毒神经氨酸酶抑制剂中的应用。
  • Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors
    作者:Mengwu Xiao、Lvjie Xu、Ding Lin、Wenwen Lian、Manying Cui、Meng Zhang、Xiaowei Yan、Shuishi Li、Jun Zhao、Jiao Ye、Ailin Liu、Aixi Hu
    DOI:10.1016/j.ejmech.2021.113161
    日期:2021.3
    A series of 4-thiazolinone derivatives (D1-D58) were designed and synthesized. All of the derivatives were evaluated in vitro for neuraminidase (NA) inhibitory activities against influenza virus A (H1N1), and the inhibitory activities of the five most potent compounds were further evaluated on NA from two different influenza viral subtypes (H3N2 and B), and then their in vitro anti-viral activities
    设计并合成了一系列4-噻唑啉酮衍生物(D1-D58)。在体外评估了所有衍生物对甲型流感病毒(H1N1)的神经氨酸酶(NA)抑制活性,并进一步评估了来自两种不同流感病毒亚型(H3N2和B)的五种最有效化合物对NA的抑制活性,然后使用细胞病变效应(CPE)降低法评估其体外抗病毒活性。结果表明,大多数目标化合物均显示出中等至良好的NA抑制活性。化合物D18对IC 50的抑制作用最强H1N1流感亚型的抗药性值为13.06μM。中所选择的化合物,D18和D41被证明是针对流感病毒H3N2亚型的最有效的抑制剂(IC 50 = 15.00μM和IC 50 = 14.97μM,分别地)。D25是对抗B型流感最有效的化合物(IC 50 = 16.09μM)。此外,在细胞测定中,D41对N1-H275Y变体显示出比参考化合物Oseltamivir和Amantadine低的毒性和更高的效力。结构-活性关系(SAR)分析表明,引入4-CO
  • 4-Hydroxy-3-quinolinecarboxamides with antiarthritic and analgesic activities
    作者:Francois Clemence、Odile Le Martret、Francoise Delevallee、Josette Benzoni、Alain Jouanen、Simone Jouquey、Michel Mouren、Roger Deraedt
    DOI:10.1021/jm00402a034
    日期:1988.7
    by the oral route as antiinflammatory agents in carrageenin-induced foot edema and adjuvant-induced arthritis and as analgesic agents in the acetic acid induced writhing test. Among the most active molecules, some have shown both analgesic and acute antiinflammatory activities. Others, such as compounds 24, 37, and 52, were only powerful peripherally acting analgesics. Compound 52, being active at 1
    已经合成了一系列的4-羟基-3-喹啉甲酰胺,并通过口服途径评价了角叉菜胶引起的足部水肿和佐剂引起的关节炎中的抗炎药,以及乙酸引起的扭体试验中的镇痛药。在最活跃的分子中,有些已经显示出止痛和急性抗炎活性。其他化合物,例如化合物24、37和52,仅是有效的外周镇痛药。活性为1 mg / kg(ED50)的化合物52是该系列中最有效的化合物。一些在2位上被醇,酯或胺官能团取代的类似物显示出与吡罗昔康相同的有效抗关节炎活性,并且在炎症和伤害感受的急性试验中也具有活性。他们抑制了微摩尔浓度的环氧合酶和5-脂氧合酶的活性。化合物102(RU 43526)显示出有效的抗关节炎活性(佐剂诱发的关节炎,ED50 = 0.7 mg / kg,口服)和胃肠道耐受性(ED100大于250 mg / kg,口服),因此,目前正在接受广泛的药理评估。
  • Certain 1,3-dihydro-1-[heterocyclic)imino]-furo-[3,4-b]quinoline 9-ol
    申请人:Roussel Uclaf
    公开号:US04736033A1
    公开(公告)日:1988-04-05
    A 4-hydroxy-3-quinoline-carboxamides of the formula ##STR1## wherein X is in the 5,6,7 or 8-position and is selected from the group consisting of hydrogen, halogen, alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 4 carbon atoms, --CH.sub.3, --OCF.sub.3 or --SCF.sub.3, R.sub.1 is selected from the group consisting of hydrogen and alkyl of 1 to 4 carbon atoms, R.sub.2 is selected from the group consisting of a heterocycle connected to the nitrogen by a carbon atom selected from thiazolyl, 4,5-dihydro-thiazolyl, pyridinyl, oxazolyl, isoxazolyl, imidazolyl, pyrimidinyl or tetrazolyl, all optionally substituted with alkyl of 1 to 4 carbon atoms or phenyl optionally substituted with at least one member of the group consisting of --OH, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, --CH.sub.3, --NO.sub.2 or halogen, R.sub.3 is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms or aryl, R.sub.4 is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms or aryl, and their non-toxic, pharmaceutically acceptable acid addition salts and salts with non-toxic, pharmaceutically acceptable bases having very good analgesis activity and a non-negligible anti-inflammatory activity and novel intermediates.
    式##STR1##中的4-羟基-3-喹啉羧酰胺,其中X位于5、6、7或8位,并选自由氢、卤素、1至5个碳原子的烷基、1至4个碳原子的烷氧基、--CH.sub.3、--OCF.sub.3或--SCF.sub.3的群,R.sub.1选自由氢和1至4个碳原子的烷基的群,R.sub.2选自由氮原子连接的杂环,所述杂环由噻唑基、4,5-二氢噻唑基、吡啶基、噁唑基、异噁唑基、咪唑基、嘧啶基或四唑基中的碳原子选自,所有这些基可选择地用1至4个碳原子的烷基或苯基取代,所述苯基可选择地用--OH、1至4个碳原子的烷基、1至4个碳原子的烷氧基、--CH.sub.3、--NO.sub.2或卤素中的至少一种成员取代,R.sub.3选自由氢、1至4个碳原子的烷基或芳基的群,R.sub.4选自由氢、1至4个碳原子的烷基或芳基的群,以及它们的无毒、药学上可接受的酸盐和与非毒性、药学上可接受的碱形成的盐,具有非常好的镇痛活性和非可忽略的抗炎活性和新颖的中间体。
  • 4-Hydroxy-3-quinoline-carboxylic acid derivatives
    申请人:Roussel Uclaf
    公开号:US04486438A1
    公开(公告)日:1984-12-04
    Novel 4-hydroxy-3-quinoline-carboxamides of the formula ##STR1## wherein X is in the 5,6,7 or 8-position and is selected from the group consisting of hydrogen, halogen, alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 4 carbon atoms, --CF.sub.3, --OCF.sub.3 and --SCF.sub.3, R.sub.1 is selected from the group consisting of hydrogen and alkyl of 1 to 4 carbon atoms, R.sub.2 is selected from the group consisting of thiazolyl, 4,5-dihydro-thiazolyl, pyridinyl, oxazolyl, isoxazolyl, imidazolyl, pyrimidinyl and tetrazolyl, all optionally substituted with alkyl of 1 to 4 carbon atoms and phenyl optionally substituted with at least one member of the group consisting of --OH, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, --CF.sub.3, --NO.sub.2 and halogen R.sub.3 is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms and aryl, R.sub.4 is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms and aryl, R.sub.5 is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms and ##STR2## R.sub.5 ' is selected from the group consisting of alkyl of 1 to 4 carbon atoms and aryl and their non-toxic, pharmaceutically acceptable acid addition salts and salts with non-toxic, pharmaceutically acceptable bases having very good analgesic activity and a non-negligible anti-inflammatory activity and novel intermediates.
    新型4-羟基-3-喹啉羧酰胺的化学式为##STR1##其中X位于5,6,7或8位,并选自由氢、卤素、1至5个碳原子的烷基、1至4个碳原子的烷氧基、--CF.sub.3、--OCF.sub.3和--SCF.sub.3组成的群,R.sub.1选自由氢和1至4个碳原子的烷基组成的群,R.sub.2选自噻唑基、4,5-二氢噻唑基、吡啶基、噁唑基、异噁唑基、咪唑基、嘧啶基和四唑基组成的群,所有这些基可选择地用1至4个碳原子的烷基和苯基替代,所述苯基可选择地用--OH、1至4个碳原子的烷基、1至4个碳原子的烷氧基、--CF.sub.3、--NO.sub.2和卤素中的至少一种成员替代,R.sub.3选自由氢、1至4个碳原子的烷基和芳基组成的群,R.sub.4选自由氢、1至4个碳原子的烷基和芳基组成的群,R.sub.5选自由氢、1至4个碳原子的烷基和##STR2##R.sub.5'选自由1至4个碳原子的烷基和芳基组成的群,以及它们的无毒、药学上可接受的酸盐和与无毒、药学上可接受的碱盐具有非常好的镇痛活性和不可忽视的抗炎活性的盐和新型中间体。
查看更多